PDF herunterladen
Fortschr Neurol Psychiatr 2013; 81(9): 503-510
DOI: 10.1055/s-0033-1350457
Originalarbeit
© Georg Thieme Verlag KG Stuttgart · New York

Impulsiv-zwanghafte Verhaltensstörungen in einer deutschen Stichprobe ambulant versorgter Parkinson-Patienten

Impulsive-Compulsive Behaviours in a German Parkinson’s Disease Outpatient Sample
K. Rohde
1   Division für Neurodegenerative Erkrankungen, Klinik für Neurologie, Technische Universität Dresden
,
O. Riedel
2   Institut für Klinische Psychologie und Psychotherapie, TU Dresden
,
U. Lueken
2   Institut für Klinische Psychologie und Psychotherapie, TU Dresden
,
S. Rietzel
1   Division für Neurodegenerative Erkrankungen, Klinik für Neurologie, Technische Universität Dresden
2   Institut für Klinische Psychologie und Psychotherapie, TU Dresden
,
M. Fauser
1   Division für Neurodegenerative Erkrankungen, Klinik für Neurologie, Technische Universität Dresden
,
C. Ossig
1   Division für Neurodegenerative Erkrankungen, Klinik für Neurologie, Technische Universität Dresden
,
H. Reichmann
3   Klinik für Neurologie, Technische Universität Dresden
,
A. Storch
1   Division für Neurodegenerative Erkrankungen, Klinik für Neurologie, Technische Universität Dresden
4   Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE) Dresden
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
28. August 2013 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Zusammenfassung

Hintergrund: Impulsiv-zwanghafte Verhaltensstörungen (Impulsive Compulsive Behaviours, ICBs) sind häufige, therapiebedingte Komplikationen beim idiopathischen Parkinsonsyndrom (IPS). Sie umfassen Impulskontrollstörungen (Impulsive Compulsive Disorders, ICDs), repetitive Verhaltensstörungen (Repetitive Behaviour, RB) und das Dopamin-Dysregulations-Syndrom (DDS).

Methoden: In einer multizentrischen, prospektiven Longitudinalstudie an n = 739 Patienten mit IPS wurde eine Teilstichprobe (n = 72) mit dem Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s Disease (QUIP) untersucht. Die Ergebnisse wurden mit soziodemografischen, klinischen und neuropsychologischen Parametern in Verbindung gesetzt.

Ergebnisse: Bei 60 % der Stichprobe lag mindestens eine ICB vor, am häufigsten waren RBs (47 %). Patienten mit ICB wiesen höhere Dopaminagonisten-Dosen auf (343 ± 177 mg vs. 390 ± 153 mg; p < 0,01). Bei einer Subgruppenanalyse zeigte sich eine Assoziation zwischen RBs, nicht aber ICDs und Pramipexol (Levodopa-Äquivalenzdosis: 273 ± 225 mg bzw. 53 ± 106 mg vs. 151 ± 209 mg bei Pat. ohne ICBs). Patienten mit ICDs wiesen stärkere Dyskinesien auf (UPDRS IV: 1,8 ± 1,6 vs. 0,6 ± 1,1 Punkte; p = 0,012) und Patienten mit multiplen ICBs eine höhere Erkrankungsdauer (9,3 ± 5,0 vs. 6,2 ± 4,0 Jahre; p = 0,026) und geringere Lebensqualität (PDQ39: 29,9 ± 13,8 vs. 20,3 ± 13,4 Punkte; p = 0,036) als Patienten ohne ICB.

Schlussfolgerungen: ICBs sind auch bei ambulant versorgten IPS-Patienten mit vergleichsweise geringer Erkrankungsdauer und -schwere häufig und mit der Dosis von Dopaminagonisten assoziiert. Da sie schwerwiegende psychosoziale Konsequenzen haben können, sind ihre Detektion und Therapie wichtig.

Abstract

Background: Impulsive-compulsive behaviours (ICBs) are frequent complications of Parkinson’s disease (PD), associated with treatment by dopamine agonists (DAs). These include impulse control disorders (ICDs), repetitive behaviour (RB) and the dopamine-dysregulation syndrome (DDS).

Methods: A subsample of 72 patients of a large longitudinal study (n = 739) was screened with the Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s disease (QUIP). Results were associated with socio-demographic, clinical and neuropsychological parameters.

Results: A large proportion of the sample reported ICBs (60 %), RBs were most frequent (47 %). Patients with ICBs consumed higher doses of DAs (343 ± 177 mg vs. 390 ± 153 mg; p < 0.01). Pramipexole was associated with RB but not ICDs (273 ± 225 mg and 53 ± 106 mg vs. 151 ± 209 mg in patients without ICB). Patients with ICDs reported more dyskinesias (UPDRS IV: 1.78 ± 1.6 vs. 0.55 ± 1.1 points; p = 0.012) and patients with multiple ICBs a longer duration of PD (9.3 ± 5.0 vs. 6.2 ± 4.0 years; p = 0.026) and worse quality of life (PDQ39: 29.9 ± 13.8 vs. 20.3 ± 13.4 points; p = 0.036) compared to patients without any ICB.

Conclusions: ICBs are frequent even in outpatients with moderate duration and severity of PD and associated with DA dose. Because of possible serious psychosocial consequences, detecting and managing them is of high importance.

Schlüsselwörter

Parkinson - IPS - Impulskontrollstörungen - Therapie - Dopaminagonisten

Key words

Parkinson’s disease - PD - impulse control disorders - treatment - dopamine agonists
 

  • Literatur

  • 1 Aarsland D, Bronnick K, Ehrt U et al. Neuropsychiatric symptoms in patients with Parkinson’s disease and dementia: frequency, profile and associated caregiver stress. J Neurol Neurosurg Psychiatry 2007; 78: 36-42
    CrossrefPubMedSuche in Google Scholar
  • 2 Voon V, Fox SH. Medication-related impulse control and repetitive behaviors in Parkinson’s disease. Arch Neurol 2007; 64 (08) 1089-1096
    CrossrefPubMedSuche in Google Scholar
  • 3 Grant JE, Potenza MN, Weinstein A et al. Introduction to Behavioral Addictions. Am J Drug Alcohol Abuse 2010; 36 (05) 233-241
    CrossrefPubMedSuche in Google Scholar
  • 4 WHO. Internationale Klassifikation psychischer Störungen. ICD-10 Kapitel V (F). Bern: Hans Huber; 2004 3. korrigierte edn.
    PubMedSuche in Google Scholar
  • 5 Fernandez HH, Friedman JH. Punding on L-Dopa. Movement Disord 1999; 14 (05) 836-838
    CrossrefPubMedSuche in Google Scholar
  • 6 Friedman JH. Punding on levodopa. Biol Psychiatry 1994; 36 (05) 350-351
    PubMedSuche in Google Scholar
  • 7 Giovannoni G, O’Sullivan JD, Turner K et al. Hedonistic homeostatic dysregulation in patients with Parkinson’s disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry 2000; 68: 423-428
    CrossrefPubMedSuche in Google Scholar
  • 8 Weintraub D, Koester J, Potenza MN et al. Impulse Control Disorders in Parkinson’s disease. A cross-sectional study of 3090 patients. Arch Neurol 2010; 67 (05) 589-595
    CrossrefPubMedSuche in Google Scholar
  • 9 Giladi N, Weitzman N, Schreiber S et al. New onset heightened interest or drive for gambling, shopping, eating or sexual activity in patients with Parkinson’s disease: the role of dopamine agonist treatment and age at motor symptoms onset. J Psychopharmacol 2007; 21 (05) 501-506
    PubMedSuche in Google Scholar
  • 10 Spencer AH, Rickards H, Fasano A et al. The prevalence and clinical characteristics of punding in Parkinson’s disease. Movement Disord 2011; 26 (04) 578-586
    CrossrefPubMedSuche in Google Scholar
  • 11 Pezzella RF, Colosimo C, Vanacore N et al. Prevalence and clinical features of hedonistic homeostatic dysregulation in Parkinson’s disease. Movement Disord 2005; 20 (01) 77-81
    CrossrefPubMedSuche in Google Scholar
  • 12 Chiang HL, Huang YS, Chen ST et al. Are there ethnic differences in impulsive/compulsive behaviors in Parkinson’s disease?. Europ J Neurol 2012; 19 (03) 494-500
    CrossrefPubMedSuche in Google Scholar
  • 13 Joutsa J, Martikainen K, Vahlberg T et al. Impulse control disorders and depression in Finnish patients with Parkinson’s disease. Parkinsonism Rel Disord 2012; 18 (02) 155-160
    CrossrefPubMedSuche in Google Scholar
  • 14 Kummer A, Dias FMV, Cardoso F et al. Low frequency of bipolar disorder, dopamine dysregulation syndrome, and punding in Brazilian patients with Parkinson’s disease. Rev Bras Psiquiatr 2010; 32: 62-65
    CrossrefPubMedSuche in Google Scholar
  • 15 Lim SY, Tan ZK, Ngam PI et al. Impulsive-compulsive behaviors are common in Asian Parkinson’s disease patients: Assessment using the QUIP. Parkinsonism Rel Disord 2011; 17 (10) 761-764
    CrossrefPubMedSuche in Google Scholar
  • 16 Antonini A, Siri C, Santangelo G et al. Impulsivity and compulsivity in drug-naïve patients with Parkinson’s disease. Movement Disord 2011; 26 (03) 464-468
    CrossrefPubMedSuche in Google Scholar
  • 17 Evans AH, Lawrence A, Potts J et al. Factors influencing susceptibility to compulsive dopaminergic drug use in Parkinson disease. Neurology 2005; 65: 1570-1574
    CrossrefPubMedSuche in Google Scholar
  • 18 Mamikonyan E, Siderowf AD, Duda JE et al. Long-term follow-up of impulse control disorders in Parkinson’s disease. Movement Disord 2008; 23 (01) 75-80
    CrossrefPubMedSuche in Google Scholar
  • 19 Weintraub D, Siderowf A, Potenza MN et al. Dopamine Agonist Use is Associated with Impulse Control Disorders in Parkinson’s Disease. Arch Neurol 2006; 63 (07) 969-973
    CrossrefPubMedSuche in Google Scholar
  • 20 Sohtaoğlu M, Demiray DY, Kenangil G et al. Long term follow-up of Parkinson’s disease patients with impulse control disorders. Parkinsonism Rel Disord 2010; 16 (05) 334-337
    CrossrefPubMedSuche in Google Scholar
  • 21 Lawrence AJ, Blackwell AD, Barker RA et al. Predictors of punding in Parkinson’s disease: Results from a questionnaire survey. Movement Disord 2007; 22 (16) 2339-2345
    CrossrefPubMedSuche in Google Scholar
  • 22 Isaias IU, Siri C, Cilia R et al. The relationship between impulsivity and impulse control disorders in Parkinson’s disease. Movement Disord 2008; 23 (03) 411-415
    CrossrefPubMedSuche in Google Scholar
  • 23 Djamshidian A, O’Sullivan SS, Wittmann BC et al. Novelty seeking behaviour in Parkinson’s disease. Neuropsychologia 2011; 49 (09) 2483-2488
    CrossrefPubMedSuche in Google Scholar
  • 24 O’Sullivan SS, Loane CM, Lawrence AD et al. Sleep disturbance and impulsive-compulsive behaviours in Parkinson’s disease. J Neurol Neurosurg Psychiatry 2011; 82 (06) 620-622
    CrossrefPubMedSuche in Google Scholar
  • 25 Bentivoglio AR, Baldonero E, Ricciardi L et al. Neuropsychological features of patients with Parkinson’s disease and impulse control disorders. Neurol Sci 2012; online-Publikation, DOI: 10.1007/s10072-012-1224-5
    PubMedSuche in Google Scholar
  • 26 Siri C, Cilia R, Gaspari D et al. Cognitive status of patients with Parkinson’s disease and pathological gambling. J Neurol 2009; 257 (02) 247-252
    PubMedSuche in Google Scholar
  • 27 Vitale C, Santangelo G, Trojano L et al. Comparative neuropsychological profile of pathological gambling, hypersexuality, and compulsive eating in Parkinson’s disease. Movement Disord 2011; 26 (05) 830-836
    CrossrefPubMedSuche in Google Scholar
  • 28 Weintraub D, Hoops S, Shea JA et al. Validation of the questionnaire for impulsive-compulsive disorders in Parkinson’s disease. Movement Disord 2009; 24 (10) 1461-1467
    CrossrefPubMedSuche in Google Scholar
  • 29 Hughes A, Daniel S, Kilford L et al. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181-184
    CrossrefPubMedSuche in Google Scholar
  • 30 Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med 2004; 256 (03) 183-194
    CrossrefPubMedSuche in Google Scholar
  • 31 Balzer-Geldsetzer M, Braga da Costa AS, Kronenbürger M et al. Parkinson’s Disease and Dementia: A Longitudinal Study (DEMPARK). Neuroepidemiology 2011; 37: 168-176
    CrossrefPubMedSuche in Google Scholar
  • 32 Hoehn M, Yahr M. Parkinsonism: onset, progression and mortality. Neurology 1967; 17: 427-442
    CrossrefPubMedSuche in Google Scholar
  • 33 Fahn S. Unified Parkinson’s Disease Rating Scale. In: Fahn S, Calne D, Florham ParkNJ, (eds.) Recent Developments in Parkinson’s Disease. MacMillan Healthcare Information; 1987: 153-163
    Suche in Google Scholar
  • 34 Tomlinson CL, Stowe R, Patel S et al. Systematic review of Levodopa dose equivalency reporting in Parkinson’s disease. Movement Disord 2010; 25 (15) 2649-2653
    CrossrefPubMedSuche in Google Scholar
  • 35 Folstein M, Folstein S, McHugh P. Mini-Mental state: a practical method for grading the mental state of patients by the clinician. J Psychiatr Res 1975; 12: 189-198
    CrossrefPubMedSuche in Google Scholar
  • 36 Kalbe E, Riedel O, Kohn N et al. Sensitivität und Spezifität des „Parkinson Neuropsychometric Dementia Assessment“ (PANDA): Ergebnisse der GEPAD-Studie. Aktuel Neurol 2007; 34: 140-146
    Thieme ConnectPubMedSuche in Google Scholar
  • 37 Welsh KA, Butters N, Mohs RC et al. The Consortium-to-Establish-a-Registry-for-Alzheimer’s-Disease (CERAD). A normative study of the neuropsychological battery. Neurology 1994; 44 (04) 609-614
    CrossrefPubMedSuche in Google Scholar
  • 38 Burke WJ, Nitcher RL, Roccaforte WH et al. A prospective evaluation of the Geriatric Depression Scale in an outpatient geriatric assessment-center. J Ame Geriatr Soc 1992; 40 (12) 1227-1230
    PubMedSuche in Google Scholar
  • 39 Schrag A, Barone P, Brown R et al. Depression rating scales in Parkinson’s disease: critique and recommendations. Movement Disord 2007; 22 (08) 1077-1092
    CrossrefPubMedSuche in Google Scholar
  • 40 Greiner W, Weijnen T, Nieuvenhuizen M et al. A European EQ-5D VAS valuation set. In: Brooks R, Rabin R, de Charro FDortrecht, (eds.) The measurement and valuation of health status using EQ-5D – A European perspective. Kluwer; 2003: 103-142
    CrossrefSuche in Google Scholar
  • 41 Jenkinson C, Fitzpatrick R, Peto V et al. The Parkinson’s Disease Questionnaire (PDQ-39): development and validation of a Parkinson’s disease summary index score. Age Ageing 1997; 26 (05) 353-357
    CrossrefPubMedSuche in Google Scholar
  • 42 Lüken U, Seidl U, Schwarz M et al. Die Apathy Evaluation Scale: Erste Ergebnisse zu den psychometrischen Eigenschaften einer deutschsprachigen Übersetzung der Skala. Fortschr Neurol Psychiat 2006; 74: 714-722
    Thieme ConnectPubMedSuche in Google Scholar
  • 43 Weintraub D, Hoops S, Shea JA et al. Validation of the Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s disease. Movement Disord 2009; 24 (10) 1461-1467
    CrossrefPubMedSuche in Google Scholar
  • 44 Silveira-Moriyama L, Evans AH, Katzenschlager R et al. Punding and dyskinesias. Movement Disord 2006; 21 (12) 2214-2217
    CrossrefPubMedSuche in Google Scholar
  • 45 Voon V, Fernagut PO, Wickens J et al. Chronic dopaminergic stimulation in Parkinson’s disease: from dyskinesias to impulse control disorders. Lancet Neurol 2009; 8: 1140-1149
    CrossrefPubMedSuche in Google Scholar
  • 46 Ray NJ, Strafella AP. Imaging impulse control disorders in Parkinson’s disease and their relationship to addiction. J Neural Transm 2012; online-Publikation, DOI: 10.1007/s00702-012-0933-5
    PubMedSuche in Google Scholar
  • 47 Voon V, Pessiglione M, Brezing C et al. Mechanisms underlying dopamine-mediated reward bias in compulsive behaviors. Neuron 2010; 65 (01) 135-142
    CrossrefPubMedSuche in Google Scholar
  • 48 Fasano A, Pettorruso M, Ricciardi L et al. Punding in Parkinson’s disease: The impact of patient’s awareness on diagnosis. Movement Disord 2010; 25 (09) 1297-1299
    CrossrefPubMedSuche in Google Scholar
  • 49 Papay K, Mamikonyan E, Siderowf AD et al. Patient versus informant reporting of ICD symptoms in Parkinson’s disease using the QUIP: Validity and variability. Parkinsonism Rel Disord 2011; 17 (03) 153-155
    CrossrefPubMedSuche in Google Scholar
  • 50 Evans AH, Strafella AP, Weintraub D et al. Impulsive and compulsive behaviors in Parkinson’s disease. Movement Disord 2009; 24 (11) 1561-1570
    CrossrefPubMedSuche in Google Scholar
  • 51 Ondo WG, Lai D. Predictors of impulsivity and reward seeking behavior with dopamine agonists. Parkinsonism Rel Disord 2008; 14 (01) 28-32
    CrossrefPubMedSuche in Google Scholar
  • 52 Ávila A, Cardona X, Martín-Baranera M et al. Impulsive and compulsive behaviors in Parkinson’s disease: A one-year follow-up study. Neurol Sci 2011; 310 (01) 197-201
    CrossrefPubMedSuche in Google Scholar
  • 53 Weintraub D. Dopamine and impulse control disorders in Parkinson’s disease. Ann Neurol 2009; 64 (Suppl. 02) S93-S100
    CrossrefPubMedSuche in Google Scholar